

Table 2. Main characteristics related to liver disease in patients with COVID-19 infection in different Chinese regions based on a series of case reports.

Author, Year	Country	Sample size (n)	Abnormal AST (%)	AST (IU/L)	Abnormal ALT (%)	ALT (IU/L)	Male, n (%)	Age (years)	Disease severity		History of liver diseases (%)	Drugs		
									Severe (%)	Non-severe (%)		<i>Antibiotic drugs (%)</i>	<i>Antiviral drugs (%)</i>	<i>Antifungal drugs (%)</i>
Guan WJ 2020 ¹¹	China (Multi-center)	1099	168 (22.2)	NA	158 (21.3)	NA	640 (58.2)	47.0 (35.0 - 58.0)	173 (15.7)	926 (84.3)	23 (2.1)	632 (57.5)	393 (35.8)	30 (2.7)
Xu XW, 2020 ¹²	China (Zhejiang)	62	10 (16.1)	26 (20 - 32)	NA	22 (14 - 34)	36 (58.1)	41.0 (32.0 - 52.0)	NA	NA	7 (11.3)	28 (45.2)	55 (88.7)	NA
Chen NS, 2020 ⁵	China (Wuhan)	99	35 (35.3)	34 (26 - 48)	28 (28.2)	39 (22 - 53)	67 (68.7)	55.5 ± 35.1	NA	NA	11 (11.1)	70 (70.7)	75 (75.8)	15 (15.2)
Chen L, 2020 ¹³	China (Wuhan)	29	7 (24.1)	NA	5 (17.2)	NA	21 (72.4)	56.0*	14 (48.3)	15 (51.7)	NA	NA	NA	NA
Wang DW, 2020 ¹⁴	China (Wuhan)	138	NA	31 (24 - 51)	NA	24 (16 - 40)	75 (54.3)	56.0 (42.0 - 68.0)	36 (26.1)	102 (73.9)	4 (2.9)	89 (64.5)	124 (89.9)	NA
Pan F, 2020 ¹⁵	China (Wuhan)	21	NA	32±20 (15 - 95)	NA	42±31 (12 - 107)	6 (28.6)	40.0 ± 9.0	0 (0.0)	21 (100.0)	NA	NA	NA	NA
Liu C, 2020 ¹⁶	China (Multi-center)	32	2 (6.2)	25 (19 - 32)	9 (28.1)	26 (17 - 46)	20 (62.5)	38.5 (26.3-45.8)	4 (12.5)	28 (87.5)	1 (3.13)	NA	NA	NA
Huang C 2020 ¹⁷	China (Wuhan)	41	15 (36.6)	34 (26 - 48)	NA	32 (21 -50)	30 (73.2)	49.0 (41.0 - 58.0)	13 (31.7)	28 (68.3)	1 (2.4)	41 (100.0%)	38 (92.7%)	NA
Chen HJ 2020 ¹⁸	China (Wuhan)	9	3 (33.3)	24 (21 - 119)	3 (33.3)	16 (11 -58)	0 (0)	28 (26 - 34)	0 (0.0)	9 (100.0)	NA	9 (100.0%)	6 (66.7%)	NA

AST: aspartate aminotransferase. ALT: alanine aminotransferase. Liver diseases: any liver disease that can cause liver enzyme changes, such as viral hepatitis, autoimmune hepatitis, etc. NA: not available. Normal range for AST and ALT: AST < 40 IU/L and ALT < 40 IU/L.

*: Median, no interquartile range